lurtotecan has been researched along with camptothecin in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (44.12) | 18.2507 |
| 2000's | 19 (55.88) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, Y; Kohn, KW; Pommier, Y; Shi, LM; Weinstein, JN | 1 |
| St Claire, RL; Stafford, CG | 1 |
| Besterman, JM; Brown, HR; Emerson, DL; Evans, MG; Leitner, PP; Luzzio, MJ; Shaffer, JE; Sternbach, DD; Uehling, D; Vuong, A | 1 |
| Creemers, GJ; de Boer-Dennert, M; Gerrits, CJ; Harteveld, M; Kunka, R; Marijnen, Y; Planting, AS; Schellens, JH; Selinger, K; Verweij, J; Wissel, P | 1 |
| Aureche, C; Depee, S; Selinger, K; Smith, G | 1 |
| Besterman, JM | 1 |
| Burke, TG; Warner, DL | 1 |
| Creemers, GJ; de Boer-Dennert, M; DePee, S; Gerrits, CJ; Harteveld, M; Planting, AS; Pritchard, JF; Schellens, JH; Verweij, J; Wissel, P | 1 |
| de Jonge, MJ; Gerrits, CJ; Schellens, JH; Stoter, G; Verweij, J | 1 |
| Baker, SD; Burke, TG; Burris, HA; DePee, S; Eckardt, JR; Eckhardt, SG; Fields, S; Kuhn, JG; Kunka, R; Littlefield, D; Rodriguez, G; Rothenberg, ML; Rowinsky, EK; Smith, L; Thurman, A; Von Hoff, DD; Warner, DL; White, L; Wissel, P | 1 |
| Brown, R; McDonald, AC | 1 |
| Alden, M; Beranek, P; Cassidy, J; DeMaria, D; Depee, S; Kaye, S; Kunka, R; Littlefield, D; O'Dwyer, P; Paz-Ares, L; Reilly, D; Twelves, C; Wissel, P | 1 |
| Amantea, M; Colbern, GT; Dykes, DJ; Engbers, C; Hiller, A; Luzzio, M; Musterer, R; Pegg, E; Saville, R; Uster, P; Weng, S; Working, PK | 1 |
| Bigg, DC; Lavergne, O | 1 |
| DeMaria, D; Grochow, LB; Kaye, SB; McDonald, A; O'Dwyer, PJ; Paz-Ares, L; Selinger, K; Sludden, J; Stevenson, JP; Twelves, C; Wissel, P | 1 |
| Dombernowsky, P; Drings, P; Hanauske, AR; Morant, R; Nielsen, D; Roelvink, M; Sessa, C; Wanders, J; Wissel, P | 1 |
| Brouwer, E; de Bruijn, P; Gill, S; Hamilton, M; Kehrer, D; Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; Verweij, J | 1 |
| de Bruijn, P; Loos, WJ; Sparreboom, A; Verweij, J | 1 |
| Baccanari, D; Bendele, R; Brown, E; Chiang, S; Desjardins, JP; Dihel, LC; Emerson, DL; Gill, SC; Hamilton, M; LeRay, JD; Luzzio, MJ; Moon-McDermott, L; Moynihan, K; Richardson, FC; Tomkinson, B | 1 |
| Gamucci, T; Hanauske, A; Heinrich, B; Kaye, S; Paridaens, R; Pavlidis, N; Roelvink, M; Schellens, JH; Sessa, C; Verweij, J; Wanders, J | 1 |
| Abbott, EA; Bendele, RA; Brown, EN; Desjardins, JP; Dihel, L; Emerson, DL; Hamilton, M; Leray, JD; Ptaszynski, M; Richardson, FC; Tomkinson, BE | 1 |
| Gatto, B; Moro, S; Palumbo, M; Sissi, C; Zagotto, G | 1 |
| Bos, AM; Cameron, T; de Jonge, MJ; de Vries, EG; Groen, HJ; Hamilton, M; Kehrer, DF; Loos, WJ; Sparreboom, A; Verweij, J | 1 |
| de Bruijn, P; de Groot, FM; Hamilton, M; Kehrer, DF; Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; Verweij, J | 1 |
| Calvert, H; Cortes-Funes, H; Dombernowsky, P; Gamucci, T; Gore, ME; Hanauske, AR; Heinrich, B; Kaye, SB; Lehnert, M; Loos, WJ; Paridaens, R; Pavlidis, N; Roelvink, M; Schellens, JH; Selinger, K; Sessa, C; van Oosterom, AT; Verweij, J; Wanders, J; Wissel, PS | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Bendele, R; Brown, E; Emerson, DL; Giles, FJ; Gray, A; Hart, K; LeRay, JD; Meyer, D; Pelanne, M; Tomkinson, B | 1 |
| Eisenhauer, E; Fisher, B; Gelmon, K; Hirte, HW; MacKenzie, MJ; Ptaszynski, M; Siu, LL | 1 |
| Albitar, M; Barrett, E; Cortes, JE; Garcia-Manero, G; Giles, FJ; Hamilton, M; Kantarjian, HM; Tallman, MS; Thomas, DA; Verstovsek, S; Wierda, WG | 1 |
| Astrow, A; Barrett, E; Campos, S; Matulonis, U; Muggia, F; Roche, M; Rusk, J; Seiden, MV; Sivret, J | 1 |
| Eisenhauer, E; Fisher, B; Gelmon, K; Hamilton, M; Hirte, H; Onetto, N; Ptaszynski, M; Walsh, W | 1 |
| Baron, B; Bloch, J; Borner, M; Chollet, P; Degardin, M; Dittrich, C; Duffaud, F; Fumoleau, P; Lacombe, D; Rolland, F; Vermorken, JB | 1 |
| Barrett, E; Calvert, AH; Cameron, T; Coleman, R; Dark, GG; Eisenhauer, EA; Ellard, S; Grimshaw, R; Hamilton, M; Jayson, G; Kaye, S; Le, T; McIntosh, L; Poole, C; Swenerton, K; Trudeau, M; Vasey, P; Walsh, W | 1 |
| Takimoto, CH | 1 |
5 review(s) available for lurtotecan and camptothecin
| Article | Year |
|---|---|
Topoisomerase I inhibition by the camptothecin analog Gl147211C. From the laboratory to the clinic.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Humans; Mice; Topoisomerase I Inhibitors | 1996 |
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1997 |
[The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Macromolecular Substances; Mice; Molecular Structure; Neoplasm Proteins; Prodrugs; Structure-Activity Relationship; Topoisomerase I Inhibitors | 1998 |
Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 2000 |
Quantitation of camptothecin and related compounds.
Topics: Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 2001 |
16 trial(s) available for lurtotecan and camptothecin
| Article | Year |
|---|---|
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors | 1996 |
Determination of GI147211 in human blood by HPLC with fluorescence detection.
Topics: Antineoplastic Agents; Biotransformation; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Drug Stability; Half-Life; Humans; Hydrolysis; Infusions, Intravenous; Neoplasms; Reference Standards; Spectrometry, Fluorescence | 1995 |
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Fatigue; Female; Humans; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Stomatitis; Thrombocytopenia; Topoisomerase I Inhibitors; Treatment Outcome; Vomiting | 1997 |
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1998 |
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Time Factors; Topoisomerase I Inhibitors | 1998 |
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Treatment Outcome | 1999 |
Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome | 2000 |
Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2000 |
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Thrombocytopenia | 2002 |
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Sampling Studies; Topoisomerase I Inhibitors | 2002 |
A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Treatment Outcome | 2004 |
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Male; Metabolic Clearance Rate; Middle Aged; Mouth Mucosa; Topoisomerase I Inhibitors; Treatment Outcome | 2004 |
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Carriers; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Middle Aged; Ovarian Neoplasms; Topotecan | 2004 |
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Time Factors | 2004 |
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis | 2004 |
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Canada; Drug Administration Schedule; Endpoint Determination; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2005 |
13 other study(ies) available for lurtotecan and camptothecin
| Article | Year |
|---|---|
Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Topics: Amino Acid Substitution; Antineoplastic Agents; Binding Sites; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Hydrogen Bonding; Ligands; Models, Molecular; Molecular Conformation; Mutation; Protein Conformation; Stereoisomerism; Structure-Activity Relationship; Thermodynamics; Topoisomerase I Inhibitors | 1998 |
High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Dogs; Drug Stability; Hydrogen-Ion Concentration; Lactones; Sensitivity and Specificity; Topoisomerase I Inhibitors | 1995 |
In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Topics: Animals; Antineoplastic Agents; Body Weight; Camptothecin; Cattle; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Thymus Gland; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs.
Topics: Acetonitriles; Antineoplastic Agents, Phytogenic; Buffers; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Ethylamines; Humans; Hydrogen-Ion Concentration; Irinotecan; Lactones; Osmolar Concentration; Topotecan | 1997 |
Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Flow Cytometry; Genes, p53; Humans; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 1998 |
Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
Topics: Animals; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Drug Carriers; Drug Screening Assays, Antitumor; Enzyme Inhibitors; HT29 Cells; Humans; Liposomes; Male; Mice; Mice, Nude; Neoplasm Transplantation; Rats; Rats, Sprague-Dawley; Topoisomerase I Inhibitors; Transplantation, Heterologous; Treatment Outcome | 1998 |
Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.
Topics: Acetonitriles; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Humans; Perchlorates; Sensitivity and Specificity | 2000 |
Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Carbon Radioisotopes; Drug Carriers; Female; Humans; KB Cells; Liposomes; Mice; Mice, Nude; Sarcoma; Tissue Distribution; Topotecan; Xenograft Model Antitumor Assays | 2000 |
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Humans; Liposomes; Mice; Mice, Nude; Neoplasms; Tissue Distribution | 2001 |
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.
Topics: Adult; Antineoplastic Agents; Camptothecin; Cell Division; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Humans; Light; Male; Middle Aged; Molecular Structure; Tumor Cells, Cultured | 2002 |
[A symphony for the camptothecins].
Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan | 2003 |
OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL.
Topics: Animals; Antineoplastic Agents; Camptothecin; Disease Models, Animal; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Neoplasm Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Are there any better camptothecins than the ones we have?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Humans; Irinotecan; Pancreatic Neoplasms; Research; Topoisomerase I Inhibitors | 2003 |